Nanodigmbio-μCaler EMS Panel v1.0
1 / 5Pages

Multi-cancer Early Methylation for Screening | μCaler EMS Panel v1.0 Background The research report "Global cancer burden growing, amidst mounting need for services" released by the International Agency for Research on Cancer (IARC) of the World Health Organization (WHO), shows that in 2022, there were 20 million new cancer cases and 9.7 million cancer deaths worldwide, with lung cancer being the most common new case and cause of death globally. It is estimated that by 2050, the global incidence of new cancer cases will exceed 35 million, representing a staggering 77% increase compared to 2022. The emergence of multi-cancer early screening has epoch-making significance for the development of cancer screening and diagnosis. Compared to single-cancer detection, multi-cancer detection can achieve simultaneous detection of multiple cancers (including several cancers for which screening methods are not yet recommended), making it an inevitable trend for the future of the industry. With the development of the cancer early screening industry and the expansion of market, an in- creasing number of companies are now entering the multi-cancer early detection market, transitioning from single-cancer to multi-cancer detection. Therefore, Nanodigmbio has launched the μCaler EMS Panel v1.0, with integrates the latest upgrades of μCaler Hybrid Capture Reagents v2 and μCaler NanoBlockers. Based on the new μCaler Methylation Hybrid Capture System, which can capture and convert methylated libraries, covering the methylation status targets of candidate genes for target cancer species within the test samples. μCaler EMS Panel v1.0 (Early Methylation for Screening) covers methylation gene sites related to nine major high-incidence cancers, including selected sites approved by the NMPA and FDA, as well as those reported in literature and patents. It encom- passes nine types of cancers, including lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, carcinoma ca- ncer, prostate cancer, cervical cancer, and ovarian cancer, involving 76 methylated candidate genes associated with carcinogenesis and tumor suppression, with over 2,000 CpG sites. The probe design covers approximately 20 Kb of the human genome, providing comprehensive and accurate support for methylation early screening. Species of Cancer Lung Cancer Gastric Cancer Colorectal Carcinoma Liver Cancer Breast Cancer Carcinoma Cancer Prostatic Cancer Cervical Cancer Ovarian Cancer

Multi-Cancer Detection: Covers CpG sites of multiple genes for 9 major cancer types in a single detection. Sample Compatibility: Suitable for gDNA, cfDNA, and various level of FFPE samples. Accurate Quantification: Achieves precise quantification of methylation levels in tested samples. Efficient Capture: Combines with μCaler Total Solution for Methylation to ensure uniform data quality, higher capture eff- High Reliability: Utilizes exclusive patented probe design to comprehensively detect methylation status, providing reliable Stable Delivery: In-house nucleic acid synthesis manufacturing...

Fold 80 base penalty Figure 2. Capture performance of μCaler EMS Panel v1.0 applied to different grades of FFPE samples. A. Capture performance; B. Fold 80 base penalty. Pre-library were prepared using the NadPrep Methyl Library Preparation Module, followed by conversion using the NadPrep DNA Methyl Bisulfite Conversion Module. 500 ng of pre-library was inputted, and hybrid capture was performed using μCaler Hybrid Capture Reagents v2 and μCaler EMS Panel v1.0. Note: FFPE samples were clinical lung cancer samples, input 50 ng. Sample grading criteria: FFPE B: Main bands around 15 Kb with...

Average methylation level (%) 60 40 20 Gene Methylation Level Figure 4. Methylation level detection of μCaler EMS Panel v1.0 applied to clinical colorectal cancer and peritumoral tissue samples. A. CpG methylation level in paired colorectal cancer samples; B. CpG methylation level of colorectal cancer candidate biomarkers in clinical samples. Note: CRC: Colorectal Cancer; Pt: Peritumoral tissue. Ovarian Cancer Gene methylation level Average methylation level (%) Figure 5. The methylation level detection of μCaler EMS Panel v1.0 applied to clinical ovarian cancer and peritumoral tissue. A....

Gene methylation level * NMPA approved Figure 6. The methylation level detection of ^Caler EMS Panel v1.0 applied to clinical lung cancer tissue. A. CpG methylation level in lung cancer samples; B. CpG depth in lung cancer samples; C. CpG methylation level of lung cancer candidate biomarkers in clinical samples. Note: LC: Lung Cancer. Ordering Information Product Catalog# For research use only. Not for use in diagnostic procedures. Without the written permission of Nanodigmbio, no other individual or organization may reproduce, copy, edit, expand, reduce or translate the contents of this...